FY2027 EPS Estimates for MannKind Lowered by HC Wainwright

MannKind Corporation (NASDAQ:MNKD) – HC Wainwright decreased their FY2027 earnings per share (EPS) estimates for shares of MannKind in a report released on Thursday, April 23rd. HC Wainwright analyst B. Folkes now anticipates that the biopharmaceutical company will post earnings per share of $0.03 for the year, down from their previous forecast of $0.05. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for MannKind’s current full-year earnings is ($0.05) per share. HC Wainwright also issued estimates for MannKind’s FY2029 earnings at $0.16 EPS and FY2030 earnings at $0.54 EPS.

MannKind (NASDAQ:MNKD) last announced its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.04). The company had revenue of $111.96 million for the quarter, compared to the consensus estimate of $99.85 million. MannKind had a net margin of 1.68% and a negative return on equity of 11.21%. The company’s quarterly revenue was up 45.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.03 earnings per share.

A number of other research analysts have also commented on the stock. Wedbush reduced their price target on shares of MannKind from $10.00 to $8.00 and set an “outperform” rating for the company in a research report on Thursday, March 5th. Mizuho decreased their target price on MannKind from $10.00 to $8.00 and set an “outperform” rating on the stock in a research note on Monday, April 13th. Zacks Research upgraded MannKind from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 15th. Weiss Ratings cut shares of MannKind from a “hold (c)” rating to a “sell (d+)” rating in a research report on Monday, March 2nd. Finally, Wells Fargo & Company lowered their target price on shares of MannKind from $8.00 to $7.00 and set an “overweight” rating on the stock in a research note on Friday, February 27th. Seven equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $8.56.

MannKind Price Performance

NASDAQ MNKD opened at $2.71 on Friday. The company’s 50 day simple moving average is $3.15 and its two-hundred day simple moving average is $4.73. MannKind has a 1 year low of $2.23 and a 1 year high of $6.51. The stock has a market capitalization of $836.85 million, a PE ratio of 135.57 and a beta of 1.04.

Insider Buying and Selling at MannKind

In other MannKind news, CEO Michael Castagna acquired 100,000 shares of the business’s stock in a transaction dated Tuesday, March 10th. The stock was bought at an average price of $2.59 per share, with a total value of $259,000.00. Following the purchase, the chief executive officer owned 2,575,911 shares of the company’s stock, valued at approximately $6,671,609.49. This trade represents a 4.04% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 2.60% of the company’s stock.

Institutional Trading of MannKind

Several hedge funds have recently added to or reduced their stakes in the business. Inspire Investing LLC purchased a new stake in MannKind during the first quarter valued at about $75,000. 1492 Capital Management LLC lifted its stake in shares of MannKind by 2.7% in the 1st quarter. 1492 Capital Management LLC now owns 549,782 shares of the biopharmaceutical company’s stock valued at $1,347,000 after acquiring an additional 14,512 shares during the last quarter. Aaron Wealth Advisors LLC boosted its holdings in MannKind by 17.4% during the 1st quarter. Aaron Wealth Advisors LLC now owns 235,652 shares of the biopharmaceutical company’s stock valued at $577,000 after acquiring an additional 34,889 shares during the period. OP Asset Management Ltd purchased a new stake in MannKind during the 1st quarter valued at about $212,000. Finally, Krilogy Financial LLC bought a new position in MannKind during the 1st quarter worth approximately $28,000. 49.55% of the stock is owned by institutional investors.

MannKind Company Profile

MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company’s core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind’s lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.

Afrezza received U.S.